The global market for Induced Pluripotent Stem Cell (iPSC) was valued at US$2.1 Billion in 2024 and is projected to reach US$3.2 Billion by 2030, growing at a CAGR of 7.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Induced Pluripotent Stem Cell (iPSC) market.
Segments: Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications).
Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Induced Pluripotent Stem Cell (iPSC) Market - Key Trends & Drivers Summarized
What Are Induced Pluripotent Stem Cells (iPSCs) and Their Breakthrough Potential?
Induced pluripotent stem cells (iPSCs) are a type of stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka in 2006, who demonstrated that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. These cells possess the ability to develop into almost any type of cell within the human body, akin to embryonic stem cells, but without the associated ethical issues since they do not require the use of embryos. This groundbreaking discovery has opened up new avenues in regenerative medicine, drug discovery, and disease modeling. iPSCs are particularly promising for the development of patient-specific therapies where cells derived from the patients themselves can be used to treat a variety of conditions, from spinal cord injuries to Parkinson’s disease, potentially revolutionizing personalized medicine.How Are iPSCs Revolutionizing Medical Research and Treatment?
The versatility of iPSCs has made them a valuable tool in the field of medical research and treatment. By reprogramming cells from patients with specific genetic disorders, scientists can create iPSCs that contain the same genetic anomalies. These iPSCs can then be used to study the pathology of diseases at a cellular level, providing insights that are not possible with other types of cells. For instance, iPSCs have been used to model diseases such as ALS, diabetes, and Alzheimer’s, allowing researchers to understand disease mechanisms and discover potential drug targets. Moreover, in the realm of drug testing, iPSCs can be used to evaluate the efficacy and safety of new pharmaceuticals before they are tested in humans, reducing the reliance on animal testing and improving the predictability of drug responses. These applications not only enhance our understanding of complex diseases but also pave the way for more effective and safer treatments.What Technological Advancements Are Propelling iPSC Research?
Advancements in gene editing and tissue engineering are propelling the research and applications of iPSCs. The integration of CRISPR/Cas9 technology with iPSC technology has enabled precise alterations at the genetic level, enhancing the potential of iPSCs in therapeutic development and disease modeling. Researchers can now correct genetic defects in iPSCs derived from patients, potentially leading to cell therapy solutions that could cure inherited diseases. Additionally, the development of 3D bioprinting technologies allows for the construction of complex tissues from iPSCs, which could one day lead to the creation of organs for transplant. These technological innovations are crucial for overcoming current limitations in iPSC research, such as the efficiency of cell reprogramming and the maturity of differentiated cells, making these cells more viable for clinical applications.What Drives the Rapid Expansion of the iPSC Market?
The growth in the iPSC market is driven by several factors, including significant advancements in biomedical research and an increasing emphasis on personalized medicine. The potential of iPSCs to provide patient-specific cells for therapy and research has led to substantial investment from both public and private sectors. The expansion of regenerative medicine, seeking to restore or establish normal function by replacing damaged cells, tissues, or organs, heavily relies on innovations in iPSC technology. Moreover, the growing prevalence of chronic diseases and genetic disorders increases the demand for novel treatment strategies that iPSCs could fulfill. Additionally, regulatory support and ethical acceptance of iPSCs compared to embryonic stem cells encourage further development and application of this technology. These drivers collectively foster a dynamic and rapidly advancing market, promising to revolutionize healthcare and treatment paradigms in the coming years.Report Scope
The report analyzes the Induced Pluripotent Stem Cell (iPSC) market, presented in terms of units. The analysis covers the key segments and geographic regions outlined below.Segments: Cell Type (Vascular Cells, Cardiac Cells, Neuronal Cells, Liver Cells, Immune Cells, Other Cell Types); Research Method (Cellular Reprogramming, Cell Culture, Cell Differentiation, Cell Analysis, Cellular Engineering, Other Research Methods); Application (Drug Development & Toxicology Testing, Academic Research, Regenerative Medicine, Other Applications).
Geographic Regions/Countries: World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Vascular Cells segment, which is expected to reach US$1.1 Billion by 2030 with a CAGR of a 7.5%. The Cardiac Cells segment is also set to grow at 8.2% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $937.7 Million in 2024, and China, forecasted to grow at an impressive 8.9% CAGR to reach $116.8 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Induced Pluripotent Stem Cell (iPSC) Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Induced Pluripotent Stem Cell (iPSC) Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Induced Pluripotent Stem Cell (iPSC) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Lonza Group Ltd., Evotec SE, FUJIFILM Holdings Corporation, Abcam PLC, Horizon Discovery Ltd. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 51 companies featured in this Induced Pluripotent Stem Cell (iPSC) market report include:
- Lonza Group Ltd.
- Evotec SE
- FUJIFILM Holdings Corporation
- Abcam PLC
- Horizon Discovery Ltd.
- Cell Signaling Technology, Inc.
- Cell Applications, Inc.
- Invivogen
- ALSTEM, LLC
- Censo Biotechnologies Ltd.
- Creative Bioarray
- Creative Biolabs
- Axol Bioscience Ltd.
- ID Pharma Co., Ltd.
- BlueRock Therapeutics, LLC
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What’s Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARYIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lonza Group Ltd.
- Evotec SE
- FUJIFILM Holdings Corporation
- Abcam PLC
- Horizon Discovery Ltd.
- Cell Signaling Technology, Inc.
- Cell Applications, Inc.
- Invivogen
- ALSTEM, LLC
- Censo Biotechnologies Ltd.
- Creative Bioarray
- Creative Biolabs
- Axol Bioscience Ltd.
- ID Pharma Co., Ltd.
- BlueRock Therapeutics, LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 349 |
| Published | April 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 2.1 Billion |
| Forecasted Market Value ( USD | $ 3.2 Billion |
| Compound Annual Growth Rate | 7.0% |
| Regions Covered | Global |
